MODELING OF LOCAL ANTICANCER THERAPIES USING DU-145 PROSTATE CANCER CELLS AND MONOCLONAL ANTIBODY ATEZOLIZUMAB

Žilvinas Survila1, Gintaras Zaleskis2

1 Institute of Bioscience, Life Science Center, Vilnius University, Vilnius, Lithuania

2 Laboratory of Immunology, National Cancer Institute, Vilnius, Lithuania

Pembrolizumab and atezolizumab are monoclonal antibodies approved for cancer immunotherapy targeting immunosuppressive PD-1 and PD-L1 axis used by cancer cells to avoid the host immune system [1]. Despite their efficacy in some types of cancer, they show limited capabilities in the treatment of prostate cancer. However, a combination of monoclonal antibodies with other medications was found to elicit stronger responses. The exact mechanism of such an outcome is unknown [2].

One of the possible factors which may determine treatment effectiveness is the expression of PD-L1 on cancer cells. Herein we assess the expression of PD-L1 in human prostate cell line DU-145 and evaluate atezolizumab binding efficiency to membranous PD-L1 by using flow cytometry approach. Our results show that around 70% of DU-145 cells are PD-L1 positive and atezolizumab in vitro completely saturates membranous PD-L1 at concentrations higher than 0.5 μg/ml indicating that immunotherapy directed towards PD-L1 and PD-1 axis could be effective in prostate cancer.


[1] Y. Wang et al., Advancing to the era of cancer immunotherapy, Cancer communications (London, England), 41(9), 803-829 (2021).

[2] A. Rizzo, V. Mollica, A. Cimadamore et al., Is There a Role for Immunotherapy in Prostate Cancer?, Cells; 9(9), 2051 (2020).